2021
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Bewersdorf JP, Zeidan AM. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Cancers 2021, 13: 1610. PMID: 33807279, PMCID: PMC8036734, DOI: 10.3390/cancers13071610.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic myelomonocytic leukemiaMyelodysplastic syndromeMyelomonocytic leukemiaAllogeneic hematopoietic cell transplantRed blood cell transfusionClinical symptom burdenLR-MDS patientsOverall survival benefitBlood cell transfusionHematopoietic cell transplantHigh-risk patientsMainstay of therapyErythropoiesis-stimulating agentsRisk of progressionRisk stratification toolIndividualized treatment strategiesAcute myeloid leukemiaRoutine clinical useAgent azacitidineAllo-HCTCell transfusionMost patientsSupportive careSurvival benefitSymptom burden
2020
Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
Bewersdorf JP, Zeidan AM. Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? Cells 2020, 9: 2310. PMID: 33080779, PMCID: PMC7603052, DOI: 10.3390/cells9102310.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTumor lysis syndromeAcute myeloid leukemiaLeukemic blastsMyeloid leukemiaCell adhesion moleculeAggressive intravenous fluid hydrationWhite blood cell countEndothelial cellsAdhesion moleculesDevelopment of leukostasisIntravenous fluid hydrationManagement of DICMainstay of therapyLife-threatening complicationsBlood cell countLeukemic stem cell survivalBone marrow microenvironmentIntensive chemotherapyIntravascular coagulationLysis syndromeFluid hydrationSupportive treatmentAdverse prognosisAML patientsInflammatory cytokinesFollowing in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP, Zeidan AM. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Leukemia & Lymphoma 2020, 61: 2295-2312. PMID: 32421403, PMCID: PMC7670856, DOI: 10.1080/10428194.2020.1761968.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-risk myelodysplastic syndromeAcute myeloid leukemiaMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationGenetic testingHematopoietic stem cell transplantationImmune checkpoint inhibitorsCurative treatment optionMainstay of therapyRecent therapeutic advancesStem cell transplantationCurrent treatment approachesAgent azacitidineCheckpoint inhibitorsMost patientsMDS patientsAvailable therapiesCell transplantationPatient subgroupsTreatment optionsTherapeutic advancesIDH inhibitorsIndividualized treatmentNew agents